Smith & Nephew (LON:SN) Given Hold Rating at Deutsche Bank Aktiengesellschaft

Smith & Nephew (LON:SN)‘s stock had its “hold” rating reiterated by Deutsche Bank Aktiengesellschaft in a report issued on Thursday,Digital Look reports. They currently have a GBX 1,400 price objective on the stock. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential upside of 15.27% from the company’s previous close.

SN has been the topic of several other research reports. UBS Group reissued a “neutral” rating and issued a GBX 1,300 price objective on shares of Smith & Nephew in a research note on Tuesday, May 5th. Shore Capital Group reaffirmed a “buy” rating and set a GBX 1,000 target price on shares of Smith & Nephew in a report on Tuesday, July 21st. Berenberg Bank reiterated a “hold” rating and issued a GBX 13 price target on shares of Smith & Nephew in a research report on Friday, May 1st. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,760 price target on shares of Smith & Nephew in a research note on Thursday, May 21st. Finally, Citigroup downgraded Smith & Nephew to a “buy” rating in a research report on Friday, July 10th. Four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of GBX 1,340.11.

Smith & Nephew Stock Up 1.2%

LON SN traded up GBX 14.50 on Thursday, hitting GBX 1,214.50. The company’s stock had a trading volume of 2,325,612 shares, compared to its average volume of 343,671. The stock’s fifty day simple moving average is GBX 1,132.18 and its 200-day simple moving average is GBX 1,196.24. The company has a market capitalization of £13.31 billion, a price-to-earnings ratio of 43.73, a PEG ratio of 0.46 and a beta of 0.68. The company has a debt-to-equity ratio of 62.90, a quick ratio of 0.84 and a current ratio of 2.57.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.